◎ Sugi Atlas

Atlas / Drug / Benmelstobart

Benmelstobart

drug
On this page

Also known as APL-502APL502CBT-502CBT502TQB-2450Tqb2450

Summary

Benmelstobart (CHEMBL5315042) is a phase-3 clinical-stage antibody; indicated across 18 conditions including neoplasm and small cell lung carcinoma.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Antibody
  • Indications: 18 conditions
  • Clinical trials: 64

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL5315042
NameBenmelstobart
TypeAntibody
Max phase3

Also known as: APL-502, APL502, Benmelstobart, CBT-502, CBT502, TQB-2450, Tqb2450, BENMELSTOBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
neoplasm3MONDO:0005070EFO:0000616
small cell lung carcinoma3MONDO:0008433EFO:0000702
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
kidney cancer3MONDO:0002367MONDO:0002367
endometrium neoplasm3MONDO:0021251MONDO:0011962
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
hepatocellular carcinoma3MONDO:0007256EFO:0000182
ovarian cancer3MONDO:0008170MONDO:0008170
neoplasm of mature B-cells2MONDO:0004949EFO:0000096
carcinoma of esophagus2MONDO:0019086EFO:0002916
esophageal squamous cell carcinoma2MONDO:0005580EFO:0005922
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
cholangiocarcinoma1MONDO:0019087EFO:0005221
lung neoplasm1MONDO:0021117MONDO:0008903
breast neoplasm1MONDO:0021100MONDO:0007254

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 64.

Phase distribution

PhaseTrials
PHASE236
PHASE313
PHASE1/PHASE27
PHASE14
Not specified2
PHASE41
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06931145PHASE4NOT_YET_RECRUITINGBenmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT04523272PHASE3ACTIVE_NOT_RECRUITINGA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
NCT06469879PHASE3NOT_YET_RECRUITINGA Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
NCT06955325PHASE3NOT_YET_RECRUITINGUmbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
NCT07385079PHASE3NOT_YET_RECRUITINGAnlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
NCT07535567PHASE2/PHASE3NOT_YET_RECRUITINGPostoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma
NCT03855384PHASE3UNKNOWNStudy of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
NCT04234607PHASE3UNKNOWNA Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
NCT04325763PHASE3UNKNOWNA Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
NCT04405505PHASE3UNKNOWNA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
NCT04665609PHASE3UNKNOWNThermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
NCT04809142PHASE3UNKNOWNA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
NCT04964479PHASE3UNKNOWNA Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
NCT05145218PHASE3UNKNOWNA Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
NCT05718167PHASE3UNKNOWNTQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
NCT04539977PHASE2RECRUITINGPD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
NCT05252078PHASE2RECRUITINGAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05582499PHASE2RECRUITINGFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT06109402PHASE2NOT_YET_RECRUITINGPerioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
NCT06141226PHASE2RECRUITINGPhase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
NCT06222944PHASE2NOT_YET_RECRUITINGAnlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
NCT06429397PHASE2NOT_YET_RECRUITINGAnlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
NCT06528847PHASE2RECRUITINGAdjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
NCT06621095PHASE2NOT_YET_RECRUITINGAnlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
NCT06637163PHASE2RECRUITINGBenmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
NCT06662006PHASE2RECRUITINGNal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
NCT06699498PHASE2NOT_YET_RECRUITINGNeoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06733051PHASE2RECRUITINGPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
NCT06767800PHASE2RECRUITINGA Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
NCT06874933PHASE2RECRUITINGNeoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
NCT06992336PHASE2RECRUITINGCirculating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
NCT07172412PHASE2NOT_YET_RECRUITINGOpen-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
NCT07193186PHASE2NOT_YET_RECRUITINGAnlotinib and Benmelstobart in DTC
NCT07294261PHASE2NOT_YET_RECRUITINGGarsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
NCT07371663PHASE1/PHASE2RECRUITINGAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07510594PHASE2NOT_YET_RECRUITINGA Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07537777PHASE2NOT_YET_RECRUITINGBenmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
NCT07538258PHASE2NOT_YET_RECRUITINGBenmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
NCT07538271PHASE2NOT_YET_RECRUITINGA Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
NCT07602101PHASE2NOT_YET_RECRUITINGNeoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
NCT03800706PHASE2UNKNOWNA Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin’s Lymphoma
NCT03825705PHASE1/PHASE2UNKNOWNA Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
NCT03983928PHASE1/PHASE2UNKNOWNStudy of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
NCT03991975PHASE1/PHASE2UNKNOWNStudy of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
NCT03996408PHASE1/PHASE2UNKNOWNStudy of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
NCT04002622PHASE2TERMINATEDStudy of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
NCT04236362PHASE1/PHASE2UNKNOWNA Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
NCT04306926PHASE2UNKNOWNA Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
NCT04574284PHASE2COMPLETEDA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
NCT04623333PHASE2UNKNOWNA Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
NCT04895345PHASE2COMPLETEDA Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
NCT05038813PHASE2UNKNOWNAnlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
NCT05111366PHASE2UNKNOWNTQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
NCT05311319PHASE2UNKNOWNHAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
NCT05481645PHASE2TERMINATEDEfficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
NCT05608785PHASE1/PHASE2UNKNOWNSingle-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
NCT05812430PHASE2UNKNOWNAnlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
NCT06031480PHASE2UNKNOWNAnlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
NCT03460457PHASE1UNKNOWNTolerance and Pharmacokinetics of TQB2450
NCT03897283PHASE1UNKNOWNStudy of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
NCT03910127PHASE1UNKNOWNStudy of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
NCT06116240PHASE1UNKNOWNA Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
NCT04891900Not specifiedACTIVE_NOT_RECRUITINGTQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06603974Not specifiedNOT_YET_RECRUITINGThe Efficacy and Safety of Benmelstobart for GC/EGC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem